Herantis Pharma Plc
Press release 28 Apr 2022 at 9:00 am EEST
Herantis Pharma Plc (“Herantis”), an innovative biotech company developing new disease modifying therapies for Parkinson’s disease, today announced initial results of HER-096 blood-brain barrier (BBB) penetration in dogs. The results demonstrate that following a single subcutaneous administration of HER-096, the concentration of HER-096 measured from the cerebrospinal fluid (CSF) is within the pharmacologically active level. This result is aligned with previous data obtained from rats.
These data show that subcutaneous administration allows effective brain distribution both in small and large animals and support this route of administration to be used for HER-096 in first-in-human clinical study.
Herantis aims to report the final results of the preclinical BBB-penetration studies in animals as well as the preclinical GLP safety data during the second half of 2022. Herantis’ plan is to initiate the first-in-human study with HER-096 in 2023.
“These encouraging blood-brain barrier penetration data in large animals is a very important milestone towards HER-096 clinical studies. Further, these data strengthen the compelling preclinical dataset of HER-096 for the treatment of neurodegenerative diseases like Parkinson’s disease,” said Henri Huttunen, Chief Scientific Officer of Herantis.
For more information, please contact:
Julie Silber/Gabriela Urquilla
Tel: +46 (0)7 93 486 277/+46 (0)72-396 72 19
About Herantis Pharma Plc
Herantis Pharma Plc is an innovative biotech company developing disease modifying therapies for Parkinson’s Disease. Herantis lead product HER-096, is an advanced small and synthetic chemical peptidomimetic version of the active parent CDNF protein. It combines the compelling mechanism of action of the CDNF protein with the ability to be delivered to the brain via subcutaneous administration.
The shares of Herantis are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden. For more information, please visit https://www.herantis.com.
Certified Advisor: UB Securities Ltd, Finland: +358 9 25 380 225, Sweden: +358 40 5161400